snn0029 infusion solution clinical trial intelligence

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis is a PHASE1 clinical asset sponsored by Newron Sweden AB in Amyotrophic Lateral Sclerosis. SEO and diligence focus: sNN0029 infusion solution, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by target_normalized: sNN0029 infusion solution